article thumbnail

Gene editing: beyond the hype

pharmaphorum

Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”.

article thumbnail

The new pharma collaborations driving transformative research in oncology

pharmaphorum

There are a growing number of biotech and pharma companies that have established or are establishing such end-to-end cell therapy capabilities, which can also play into how collaborations are structured in the field. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.

Research 132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How epilepsy researchers are moving the needle past anti-seizure treatments

Pharmaceutical Technology

This is particularly the case for pediatric forms of epilepsy where gene editing techniques like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are becoming more important, says Ferraro. In October 2022, mjn-neuro signed a commercialization agreement with the pharma company Neuraxpharm Group to market mjn-SERAS.

Research 264
article thumbnail

AstraZeneca cuts the ribbon on its $1bn R&D lab in Cambridge

pharmaphorum

The DISC is the biggest investment AZ has ever made, and has been hailed by the pharma company’s chief executive Pascal Soriot as the centrepiece of what he believes could one day become a biotech hub to rival Boston and San Francisco in the US.

article thumbnail

Changing Faces: agency, consultant, and investor hires from November 2022

pharmaphorum

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. The board helps Sixth Street’s healthcare and life sciences team to identify opportunities around CRISPR and gene editing. Read on for the hires headlines. New CEO joins UBC.

article thumbnail

Beyond the pandemic: the potential of mRNA technology

pharmaphorum

On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. This not only allowed Pfizer to establish a COVID-19 vaccine but the company also recently announced that it had begun a study testing an mRNA flu vaccine.

RNA 111
article thumbnail

Life Science Trends to Look Out for in 2024

XTalks

In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.